A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

被引：1
|
作者：
Lee, Hans C. [1 ]
Shah, Jatin J. [2 ]
Feng, Lei [3 ]
Morphey, Ashley [1 ]
Johnson, Ralph J. [1 ]
Wesson, Emily T. [1 ]
Wang, Michael L. [1 ]
Alexanian, Raymond [1 ]
Thomas, Sheeba K. [1 ]
Orlowski, Robert Z. [1 ,4 ]
Weber, Donna M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, 1515 Holcombe Blvd,Unit 429, Houston, TX 77030 USA
[2] Karyopharm Therapeut, Newton, MA USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2019年 / 94卷 / 12期
关键词：
DARATUMUMAB; POMALIDOMIDE;
D O I：
10.1002/ajh.25633
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E319 / E322
页数：4
相关论文
共 50 条
  • [21] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
    D S Siegel
    P Richardson
    M Dimopoulos
    P Moreau
    C Mitsiades
    D Weber
    J Houp
    C Gause
    S Vuocolo
    J Eid
    T Graef
    K C Anderson
    Blood Cancer Journal, 2014, 4 : e182 - e182
  • [22] Combination Therapy with Thalidomide, Incadronate, and Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Naoya Ochiai
    Noriko Yamada
    Ryo Uchida
    Shin-ichi Fuchida
    Akira Okano
    Mayumi Hatsuse
    Masashi Okamoto
    Eishi Ashihara
    Chihiro Shimazaki
    International Journal of Hematology, 2005, 82 : 243 - 247
  • [23] Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma
    Ochiai, N
    Yamada, N
    Uchida, R
    Fuchida, S
    Okano, A
    Hatsuse, M
    Okamoto, M
    Ashihara, E
    Shimazaki, C
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 82 (03) : 243 - 247
  • [24] Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib
    Mian, Michael
    Pescosta, Norbert
    Badiali, Stefania
    Cappelletto, Paola Cristina
    Marcheselli, Luigi
    Luminari, Stefano
    Patriarca, Francesca
    Zambello, Renato
    Pascarella, Anna
    Tagariello, Giuseppe
    Marabese, Alessandra
    Mondello, Patrizia
    Billio, Atto
    Cortelazzo, Sergio
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (05) : 944 - 947
  • [25] PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB
    Mian, M.
    Pescosta, N.
    Luminari, S.
    Badiali, S.
    Marcheselli, L.
    Patriarca, F.
    Zambello, R.
    Mondello, P.
    Pascarella, A.
    Pitini, V.
    Cortelazzo, S.
    HAEMATOLOGICA, 2014, 99 : 637 - 637
  • [26] A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
    von Lilienfeld-Toal, Marie
    Hahn-Ast, Corinna
    Furkert, Kerstin
    Hoffmann, Florian
    Naumann, Ralph
    Bargou, Ralf
    Cook, Gordon
    Glasmacher, Axel
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 81 (04) : 247 - 252
  • [27] Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)
    Jakubowiak, Andrzej J.
    Richardson, Paul G.
    Zimmerman, Todd M.
    Alsina, Melissa
    Kaufman, Jonathan L.
    Kandarpa, Malathi
    Harvey, Colleen K.
    Colson, Kathleen
    Mitchell, Monica
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Giusti, Kathy
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 1264 - 1264
  • [28] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Haruhito Totani
    Masaki Ri
    Chie Kato
    Takahiro Nakashima
    Nana Suzuki
    Shinya Hagiwara
    Takashi Kanamori
    Satsuki Murakami
    Arisa Masuda
    Shiori Kinoshita
    Takashi Yoshida
    Tomoko Narita
    Asahi Ito
    Shigeru Kusumoto
    Takashi Ishida
    Hirokazu Komatsu
    Shinsuke Iida
    International Journal of Hematology, 2016, 103 : 316 - 321
  • [29] Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study
    Facon, Thierry
    Leleu, Xavier
    Stewart, A. Keith
    Spencer, Andrew
    Rowlings, Philip
    Hulin, Cyrille
    Attal, Michel
    Garzon, Felix
    Bleickardt, Eric
    Gialelis, Konstantina
    Tuozzoli, Doreen
    Derreumaux, Dorninique
    Sonneveld, Pieter
    BLOOD, 2009, 114 (22) : 744 - 745
  • [30] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Totani, Haruhito
    Ri, Masaki
    Kato, Chie
    Nakashima, Takahiro
    Suzuki, Nana
    Hagiwara, Shinya
    Kanamori, Takashi
    Murakami, Satsuki
    Masuda, Arisa
    Kinoshita, Shiori
    Yoshida, Takashi
    Narita, Tomoko
    Ito, Asahi
    Kusumoto, Shigeru
    Ishida, Takashi
    Komatsu, Hirokazu
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (03) : 316 - 321
12345